Prev Close | 79.59 |
Open | 79.51 |
Day Low/High | 79.03 / 80.59 |
52 Wk Low/High | 68.25 / 131.94 |
Volume | 738.46K |
Prev Close | 79.59 |
Open | 79.51 |
Day Low/High | 79.03 / 80.59 |
52 Wk Low/High | 68.25 / 131.94 |
Volume | 738.46K |
Exchange | NASDAQ |
Shares Outstanding | 181.83B |
Market Cap | 14.44B |
P/E Ratio | 19.64 |
Div & Yield | N.A. (N.A) |
Algos think faster and react faster than humans can.
Cautionary tales that the IPO window might be closing at last.
In other words, wait for the downgrades.
Stocks are moving higher as the Fed said it will keep buying bonds. Rite Aid is up and Pier One is down, Take Two is a steal.
BioMarin's R&D update next Tuesday will be the biggest thing in biotech in the coming week, says Adam Feuerstein, Sr. Columnist at TheStreet.
Jim Cramer looks at stocks moving on cancer-fighting develompents, in a discussion with Mad Money Research Director Nicole Urken
Jim Cramer discusses hyper growth names with safety in discussion with Mad Money Research Director Nicole Urken
Stocks that defy correction and those ripe for correction.
The slow, steady push higher continues.
Adam Feuerstein, Sr. Columnist for TheStreet, says the BIO CEO Conference is the next big thing in biotech.
It's the bulls' turn to shine.
Adam Feuerstein, senior columnist for TheStreet, says the coming week's J.P. Morgan Healthcare Conference is the next big thing in biotech.
Adam Feuerstein, Sr. Columnist for TheStreet, says Ligand, BioMarin and Sangamo are the next big things to watch in biotech.
Trading on the S&P 500 has remained tightly contained so far.
Despite the solid performance so far this year, there's still time to get on board and ride the profit train.